Key facts
- It has raised $54.2M; the latest was Later Stage VC ($14.2M) in Jan 2026.
- Notable investors include Beijing State-owned Capital Operation and Management, Shun Xi Fund, Highlight Capital, SDIC Unity Capital, Tailong VC — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for AnlongBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AnlongBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AnlongBio
Developer of gene therapy technology intended to provide affordable and innovative treatments to patients. The company is mainly engaged in gene therapy for wet macular degeneration (wAMD) and AAV vector screening, enabling patients to obtain more effective gene therapy.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Employees
- 4
- Website
- anlongbio.com/
- Ownership
- Privately Held (backing)
AnlongBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AnlongBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AnlongBio in its N-PORT filings yet. We sweep new filings monthly.